Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances
Altimmune, Inc. (NASDAQ:ALT) is one of the best high-return penny stocks to buy right now. On February 13, Titan Partners initiated coverage of Altimmune, Inc.
Altimmune Inc. (ALT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 2,131,307 | $7,694,018 | 0.38% | |
| 2. | D E Shaw D. E. Shaw | 1,343,583 | $4,850,335 | +273% | 0% |
| 3. | Citadel Investment Group Ken Griffin | 1,337,927 | $4,829,917 | +5% | 0% |
| 4. | Knoll Capital Management Fred Knoll | 1,121,524 | $4,048,701 | 1.86% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 922,777 | $3,331,226 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.08 | 5,000 | $20,410.00 | 13,498 | 2026-01-08 | Filing | |
| $4.24 | 500 | $2,117.55 | 1,500 | 2026-01-05 | Filing | |
| $3.80 | 527 | $2,002.60 | 527 | 2025-12-29 | Filing | |
| $4.10 | 12,500 | $51,250.00 | 12,500 | 2025-12-23 | Filing | |
| $4.13 | 12,500 | $51,568.75 | 12,500 | 2025-12-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.88 | 8,184 | $56,305.92 | 55,524 | 2024-08-19 | Filing | |
| $6.93 | 7,827 | $54,241.11 | 41,958 | 2024-08-19 | Filing | |
| $15.00 | 2,714 | $40,710.00 | 2,771 | 2022-08-12 | Filing | |
| $15.01 | 20,000 | $300,268.00 | 8,498 | 2022-12-22 | Filing | |
| $20.02 | 20,000 | $400,322.00 | 236,797 | 2022-08-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,704,298 | $35,032,515 | 0% | |
| 2. | 9,491,159 | $34,263,084 | 0% | |
| 3. | 5,119,703 | $18,482,128 | 0% | |
| 4. | 2,292,410 | $8,277,782 | 0% | |
| 5. | 1,783,950 | $6,440,060 | 0% |
News See All
11 Best High Return Penny Stocks to Buy Right Now
Small-cap companies are in the spotlight amid market rotation away from technology heavyweights clobbered by premium valuation.
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating and a $20 price target.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Altimmune, Inc. (NASDAQ:ALT) Q3 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Altimmune Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
Altimmune, Inc. (NASDAQ:ALT) Q2 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Altimmune Second Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks.
Goldman Sachs Penny Stocks: Top 12 Stock Picks
In a June 24, 2025, podcast, Goldman Sachs’ Christian Mueller-Glissmann and Alexandra Wilson-Elizondo examined the dynamics driving markets.
13 Best Multibagger Stocks to Invest in Now
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies.
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to Altimmune First Quarter 2025 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session.
Hedge Fund Resource Center Billionaire Hedge Funds
